Compare UFPT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | AUPH |
|---|---|---|
| Founded | 1963 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1993 | 1999 |
| Metric | UFPT | AUPH |
|---|---|---|
| Price | $223.89 | $15.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $289.00 | $17.25 |
| AVG Volume (30 Days) | 130.6K | ★ 1.6M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.11 | N/A |
| EPS | ★ 8.61 | 0.55 |
| Revenue | ★ $597,952,000.00 | $265,808,000.00 |
| Revenue This Year | $21.91 | $21.22 |
| Revenue Next Year | $5.39 | $15.40 |
| P/E Ratio | ★ $25.34 | $28.81 |
| Revenue Growth | ★ 29.47 | 20.62 |
| 52 Week Low | $178.26 | $6.55 |
| 52 Week High | $289.57 | $16.48 |
| Indicator | UFPT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 58.50 |
| Support Level | $213.72 | $15.57 |
| Resistance Level | $222.04 | $16.07 |
| Average True Range (ATR) | 8.27 | 0.49 |
| MACD | -0.25 | -0.10 |
| Stochastic Oscillator | 80.70 | 66.17 |
UFP Technologies Inc is a designer and custom manufacturer of components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics for the medical market. The company manufactures its products by converting raw materials using laminating, molding, radio frequency and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.